Crescent Biopharma (CBIO) Change in Accured Expenses (2013 - 2026)

Crescent Biopharma (CBIO) has 14 years of Change in Accured Expenses data on file, last reported at -$3.5 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$3.5 million, down 296.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $148000.0 (down 95.03% YoY), and the FY2025 annual result was $5.4 million, up 3333.7% from the prior year.
• Change in Accured Expenses retreated to -$3.5 million in Q1 2026 per CBIO's latest filing, from -$1.1 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $2.7 million in Q2 2025 and troughed at -$3.5 million in Q1 2026.
• A 5-year average of -$104974.4 and a median of -$148473.0 in 2023 frame the typical range for Change in Accured Expenses.
• On a YoY basis, Change in Accured Expenses climbed as much as 2630.88% in 2024 and fell as far as 869.97% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at $1.2 million in 2022, then sank by 107.27% to -$85820.0 in 2023, then soared by 2630.88% to $2.2 million in 2024, then tumbled by 148.76% to -$1.1 million in 2025, then sank by 226.35% to -$3.5 million in 2026.
• Business Quant data shows CBIO's Change in Accured Expenses at -$3.5 million in Q1 2026, -$1.1 million in Q4 2025, and $2.0 million in Q3 2025.